Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib plus Bevacizumab in Advanced Solid Tumors
NCT02835833Phase 1Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Jun 2016
- Primary completion
- Apr 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of nintedanib in renal cell carcinoma (RCC), colorectal adenocarcinoma, Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) and 2 more (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoints: Number of participants with adverse events and Maximum Tolerable Dose of Nintedanib. Started Jun 2016; status: completed.
02
Drugs
nintedanib
03
Conditions
renal cell carcinoma (RCC)colorectal adenocarcinomaNonsquamous Non-Small Cell Lung Cancer (nsNSCLC)ovarian carcinomacervical carcinoma
Beyond the preview
Go deeper on NCT02835833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02835833.